# Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

> **NCT01272037** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 5018 (actual)

## Conditions studied

- Breast Ductal Carcinoma In Situ
- Invasive Breast Carcinoma
- Multicentric Breast Carcinoma
- Multifocal Breast Carcinoma
- Synchronous Bilateral Breast Carcinoma

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Systemic Chemotherapy
- **DRUG:** Tamoxifen Citrate

## Key facts

- **NCT ID:** NCT01272037
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-02-28
- **Primary completion:** 2023-02-01
- **Final completion:** 2027-01-08
- **Target enrollment:** 5018 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01272037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01272037, "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01272037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*